Rani Therapeutics RANI · Analysis & News
Heads-up: USD CPI m/m is due in 5 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD Core CPI n.s.a. m/m is due in 5 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD Core CPI is due in 5 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD Core CPI y/y is due in 5 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD CPI y/y is due in 5 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD Core CPI m/m is due in 5 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD CPI is due in 5 h (high impact). The outlook can shift noticeably around it.
The verdict on Rani Therapeutics is neutral: October's FDA program acceptance and new contract revenue are offset by a wider quarterly loss and lower cash. The RT-114 data expected by year-end is the real swing factor.
News situation · 1 items / 30 D
1 of 1 straight from the issuer or regulator
Outlook for Rani Therapeutics Holdings
Direction, typical moves and upcoming dates from our own price, news and calendar data, recalculated on every visit. An assessment, not investment advice.
What drives it
- Acceptance into the FDA's Emerging Technology Program in October is a tangible regulatory milestone for RANI.
- Contract revenue of $1.7 million appeared in the quarter against none a year earlier.
- Cash, equivalents and marketable securities of $45.3 million are said to fund operations at least through end-2027.
What argues against it
- The third-quarter net loss widened to $8.8 million from $7.9 million a year earlier.
- Cash and equivalents alone fell to $3.6 million from $18.6 million since the end of December.
- The positive regulatory progress and the mixed financials largely cancel out, leaving no firm fundamental lean either way.
What would change the picture
- RT-114 Phase 1a expansion cohort data expected by the end of 2026 could shift the picture decisively in either direction.
- High-impact US inflation releases due shortly set the broader market backdrop, with no fixed direction for the stock.
Coming up
- US: Consumer prices · expected 2.8%, previous 2.6%
- US: Jobless claims
Economic data for RANI
Full calendarComing up
- TodayUSDCPI m/m●●●Forecast 0.5%Previous 0.6%in 5h
- TodayUSDCore CPI n.s.a. m/m●●●Previous 0.4%in 5h
- TodayUSDCore CPI●●●Forecast 339.796Previous 338.896in 5h
- TodayUSDCore CPI y/y●●●Forecast 2.8%Previous 2.6%in 5h
- TodayUSDCPI y/y●●●Forecast 4.2%Previous 3.7%in 5h
- TodayUSDCore CPI m/m●●●Forecast 0.2%Previous 0.3%in 5h
- TodayUSDCPI●●●Forecast 338.683Previous 336.298in 5h
- November 12, 2026USDInitial Jobless Claims●●●in 2 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
Both worlds over time
Technical and news signals of the last 30 days on one timeline.
What is being reported about RANI
Frequently asked questions about Rani Therapeutics Holdings
What does the FDA Emerging Technology Program acceptance mean for Rani?
In October 2026 the company's technology was accepted into the FDA's Emerging Technology Program. This is treated as a tangible regulatory milestone, and it is one of the main positives in the latest quarter. It offsets, but does not outweigh, the wider quarterly loss, which is why the overall read stays balanced.
How healthy is RANI's cash position after the third quarter?
Cash, equivalents and marketable securities stood at $45.3 million at the end of September 2026, which the company says funds operations at least through end-2027. Cash and equivalents on their own fell to $3.6 million from $18.6 million since the end of December, so the composition of that cushion matters.
What is the next catalyst to watch for Rani Therapeutics?
The RT-114 Phase 1a expansion cohort data expected by the end of 2026. Latest coverage calls it the real swing factor: the quarter's regulatory progress and mixed financials largely cancel out, so the readout is what could move the fundamental picture out of its current balance.
📝 Overview Generated automatically
RANI has been the subject of 1 signals across 1 articles in the last 365 days. Sentiment skews Neutral (100%).
Breakdown: 0 bullish, 0 bearish, 1 neutral.
Most-cited catalysts: FDA Emerging Technology Program acceptance in October 2026 (1×), RT-114 Phase 1a expansion cohort data expected by end of 2026 (1×). Most-cited risk factors: Net loss grew to $8.8 million in Q3 2026 from $7.9 million in Q3 2025 (1×), Cash and cash equivalents fell to $3.6 million from $18.6 million since December 31, 2025 (1×).